Real-World Clinical Experience of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Olaparib + Abiraterone (PROceed) - PROceed

Study identifier:D0817R00074

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

A prospective observational study to evaluate real-world clinical outcomes and characteristics of patients with mCRPC treated with olaparib + abiraterone

Medical condition

metastatic castration-resistant prostate cancer

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

Male

Estimated Enrollment

250

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 15 Feb 2024
Estimated Primary Completion Date: 31 Jan 2027
Estimated Study Completion Date: 31 Jan 2027

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jan 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Merck Sharp & Dohme LLC

Inclusion and exclusion criteria